Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eXplore: Omalizumab Effects on Airway Inflammation and Remodeling in Allergic Asthma
NCT00670930Phase 4Completed
- Sponsor
- Novartis
- Start
- Apr 2008
- Primary completion
- Nov 2011
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 4 trial of omalizumab in allergic asthma, sponsored by Novartis. Started Apr 2008; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT00670930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00670930.